PolyPeptide Group AG

Headquarters: Zug, Switzerland

Employees: 1,026

SIX: PPGN +1.23%

Market Cap

CHF559.1 Million

CHF as of Jan. 1, 2024

US$664.2 Million

Market Cap History

PolyPeptide Group AG market capitalization over time

Evolution of PolyPeptide Group AG market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of PolyPeptide Group AG

Detailed Description

PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides for use in pre-clinical and clinical development, as well as for regulatory and scientific studies; and developing neoantigen therapies as personalized immunotherapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics; and provision of consultation services. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG operates as a subsidiary of Draupnir Holding B.V.

Top 1-year algo backtest: +181.22%

$10,000 in June 2023 would now be $28,122 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

PolyPeptide Group AG has the following listings and related stock indices.

Stock: SIX: PPGN wb_incandescent



Dammstrasse 19

Zug, 6300


Phone: 41 41 723 20 34